Book a Call
MDside
Book a Call

BPC-157: from Rogan’s podcast to an FDA committee vote

  • MDside
  • October 9, 2026

Key points

  • In April 2026 FDA removed BPC-157 and 11 other peptides from Category 2 after their nominations were withdrawn [2][3].
  • In July 2026 an FDA advisory committee voted 8 to 6 to add it to the compounding list. The vote is nonbinding [4][5].
  • Human data consist of 3 small uncontrolled reports, about 30 people in total, all by the same lead author [6][7][8].
  • BPC-157 is on the World Anti-Doping Agency’s prohibited list (S0) [15].

US status (October 2026): Not FDA-approved and no lawful compounding pathway; leaving Category 2 added it to no list a pharmacy may compound from. MDside providers do not prescribe it. See the BPC-157 status page.

BPC-157 had a big political year and a small evidence year. The regulatory label changed. The human data did not. If a patient asks you for it in October 2026, the honest answer is that it remains untested in controlled human trials and has no lawful compounding route.

BPC-157 moved from gyms to politics

BPC-157 is a pentadecapeptide (15 amino acids) described as stable in human gastric juice [18]. Its fame started in gyms and podcasts. In 2026 it reached politics: in an interview with Joe Rogan, US Health Secretary Robert F. Kennedy Jr. said, “I’m a big fan of peptides… I’ve used them myself and with really good effect on a couple of injuries” [1]. Critics such as biologist Paul Knoepfler answered that undoing the restrictions carries “major risks to the public” [16].

What FDA did in 2026

FDA had placed BPC-157 in Category 2 of bulk substances for compounding, the substances that may present significant safety risks. Its entry still warns that compounded BPC-157 “may pose risk for immunogenicity for certain routes of administration” [3].

On April 15, 2026 FDA announced it was removing 12 peptides from that category “due to their nominations being withdrawn by the nominators” and scheduled its Pharmacy Compounding Advisory Committee (PCAC) [2]. On July 23 the committee voted 8 to 6, with one abstention, to add BPC-157 to the compounding list. The use reviewed was ulcerative colitis [4][21]. As the American Med Spa Association noted, “The FDA is not required to follow the committee’s recommendation” [5]. FDA scientists had proposed that BPC-157 “NOT be included” [19].

  • 12: peptides removed from Category 2 in April 2026 [2]
  • 8 to 6: nonbinding FDA advisory committee vote, July 2026 [4]
  • 0: controlled human trials indexed in PubMed [9][10]

Leaving Category 2 is not permission to compound. The status tracker and our explainer on what happens after the advisory vote cover the mechanics.

The human evidence is three uncontrolled reports

This is where the enthusiasm runs into the data. All human evidence published in PubMed is three small, uncontrolled reports by the same lead author, from private US clinics:

  • Knee pain: a retrospective review with a phone survey of 16 patients after intra-articular injection (4 of them received BPC-157 plus thymosin beta-4). 14 of 16 reported relief. No control group or validated scales [6].
  • Interstitial cystitis: 12 women, injections in a single cystoscopic procedure, no control group. 10 of 12 reported complete symptom resolution [7].
  • Intravenous “safety pilot”: 2 participants, both of whom had already received IV BPC-157. Two infusions on consecutive days, with no measurable effects on the markers tested through day 3 [8].

Independent reviews reach the same conclusion. A 2025 systematic review found 36 studies, 35 preclinical and 1 clinical, and wrote: “No clinical safety data were found” [9]. A University of Utah review wrote that human data are “extremely limited” and concluded BPC-157 “should be considered investigational” [10].

The animal literature is large and comes mostly from one lab

In animals the literature is large and consistently shows healing signals in tendon, gastric mucosa and other tissues [9]. In our PubMed count (October 9, 2026), 175 of 233 BPC-157 records (about 75%) list Predrag Sikirić of the University of Zagreb as an author. That is no judgment of quality. It does mean independent replication is thin.

Reviews from the Zagreb group mention clinical trials in inflammatory bowel disease (under the code PL 14736) in which it was safe. No results of those trials are indexed as such in PubMed [18]. Independent animal studies exist: in rats and dogs the half-life was under 30 minutes [13], and a toxicology program in mice, rats, rabbits and dogs found no genetic or embryo-fetal toxicity [14].

The cancer question is theoretical and unanswered

In cultured human endothelial cells and in rats, BPC-157 has been associated with VEGFR2 receptor activation and new blood-vessel growth [11]. Tumors depend on angiogenesis, so some reviewers flag a theoretical risk. A 2026 review lists “pathological angiogenesis, carcinogenesis” among potential risks of unregulated peptides [12]. No human data confirm or rule out that concern.

Sport. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 under S0, non-approved substances, prohibited at all times [15][17].

The supporters’ case

BPC-157’s supporters make three points. Its animal literature is large and consistent across several tissues [9]. Its simple structure makes it hard to patent, and patent protection is what normally gives a company the incentive to fund the formal FDA approval process [21]. Restricting it pushes patients to the gray market. One committee member who voted yes, Dr. Melissa Loseke, cited a patient’s “research-grade” product laced with MDMA: “That’s not protecting the American people” [20]. The lack of trials does not show it fails. It shows it has not been studied in humans.

That gray-market point is the one you will meet in clinic. Products sold as research-use-only peptides are not lawful for patient use, and their identity and sterility are unknown. If you are vetting any peptide source, start with our supplier diligence checklist.

References

  1. Boston Globe. FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures. 15 April 2026. Link
  2. Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings. 16 April 2026. Link
  3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link
  4. ABC News / Good Morning America. FDA advisory committee votes to add popular peptide BPC-157 to compounding list. 23 July 2026. Link
  5. American Med Spa Association. FDA Advisory Committee Recommends Adding BPC-157 to Compounding List. 2026. Link
  6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435. Link
  7. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560. Link
  8. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143. Link
  9. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949. Link
  10. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979. Link
  11. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966. Link
  12. Moiz A, O’Keefe EL, O’Keefe JH. Dangers of injectable peptides and other unregulated “biohacking” drugs. Mo Med. 2026;123(4):337-343. PMID 42757290. Link
  13. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. Link
  14. Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036. Link
  15. World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances). Link
  16. Knoepfler P. Did Kennedy just stack the deck on FDA oversight of peptides? STAT First Opinion. 29 April 2026. Link
  17. Sport Integrity Canada. Reminder: Non-Approved Peptides Included on the Prohibited List. 27 April 2026. Link
  18. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID 21548867. Link
  19. U.S. Food and Drug Administration. PCAC July 2026 briefing document: introduction. Link
  20. Healio. FDA committee recommends looser restrictions for several peptides. 24 July 2026. Link
  21. McDermott Will & Schulte. Bulk list bound? PCAC backs majority of peptides in two-day public meeting. 27 July 2026. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.